Susan Friedman | Authors


Discussing Targeted Treatment With PARP Inhibitors for BRCA-Mutant Patients Across Tumor Types

June 25, 2019

Susan Friedman, executive director and founder, FORCE, a non-profit organization supporting education, advocacy, and research around breast and ovarian cancer, explains the relevance of PARP inhibitors and the recent developments in oncology research that may improve cancer treatment for patients with genetic mutations.